Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday, May 3rd. The brokerage presently has a $76.06 price target on the biopharmaceutical company’s stock. Vetr‘s price target suggests a potential upside of 18.05% from the stock’s previous close.
A number of other equities analysts have also weighed in on GILD. Royal Bank of Canada restated a “buy” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Tuesday, January 3rd. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. Jefferies Group LLC reiterated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a research report on Wednesday, January 4th. Cowen and Company reiterated a “buy” rating and set a $100.00 price objective on shares of Gilead Sciences in a research report on Friday, January 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $100.00 price objective on shares of Gilead Sciences in a research report on Wednesday, January 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $80.61.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.18 by $0.02. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 3.23%. The ex-dividend date is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 18.91%.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Raised to Strong-Buy at Vetr Inc.” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/05/19/gilead-sciences-inc-gild-upgraded-at-vetr-inc-updated.html.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $67.48, for a total value of $337,400.00. Following the transaction, the executive vice president now directly owns 117,988 shares of the company’s stock, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,276 shares of company stock valued at $5,932,578. 1.40% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of GILD. BlackRock Inc. raised its stake in Gilead Sciences by 2,789.0% in the first quarter. BlackRock Inc. now owns 102,969,463 shares of the biopharmaceutical company’s stock worth $6,993,686,000 after buying an additional 99,405,266 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $997,048,000. Vanguard Group Inc. raised its stake in Gilead Sciences by 7.3% in the first quarter. Vanguard Group Inc. now owns 90,693,263 shares of the biopharmaceutical company’s stock worth $6,159,886,000 after buying an additional 6,197,361 shares during the last quarter. Parnassus Investments CA raised its stake in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Gilead Sciences during the third quarter worth approximately $271,588,000. 74.19% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.